Edgewise Therapeutics Reports Third Quarter 2026 Financial Results

The Quick Take
– Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain – – Phase 3 trial for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) on track to initiate by year-end 2026 – – Dosed first patient in Phase 2 EQUINOX-HFpEF...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
BROCO ENERGY AWARDED TWO FIVE-YEAR MASSACHUSETTS STATEWIDE FUEL CONTRACTS
Statewide awards include renewable diesel, biodiesel, heating oil and eligible liquid biofuel for public entities across the Commonwealth. BOSTON, Nov. 4, 2026…
Business
Goldcom earnings missed by $0.88, revenue fell short of estimates
Business
Olin extends receivables purchase agreement termination date to July 2028
Business
